Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 15/20 | 0.82 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | PDE6D | O43924 | 1/20 | 0.49 |
| ▸ | PDE6A | P16499 | 1/20 | 0.49 |
| ▸ | PDE6G | P18545 | 1/20 | 0.49 |
| ▸ | PDE6B | P35913 | 1/20 | 0.49 |
| ▸ | PDE6C | P51160 | 1/20 | 0.49 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7955490 | 0.92 | PDE5A (0.90) | PDE5APDE4BPDE6DPDE6APDE6G | |
| SCHEMBL1082869 | 0.90 | PDE5A (1.00) | PDE5APDE4BPDE6DPDE6APDE6G | |
| SCHEMBL7947681 | 0.89 | PDE5A (0.88) | PDE5APDE4BNR3C1 | |
| SCHEMBL7947974 | 0.89 | PDE5A (0.81) | PDE5APDE4BPDE6DPDE6APDE6G | |
| SCHEMBL7961483 | 0.88 | PDE5A (0.81) | PDE5APDE4BPDE6DPDE6APDE6G | |
| SCHEMBL7955487 | 0.88 | PDE5A (0.78) | PDE5APDE4BPDE6DPDE6APDE6G | |
| SCHEMBL12551683 | 0.88 | PDE5A (0.86) | PDE5APDE4BNR3C1 | |
| SCHEMBL7956721 | 0.88 | PDE5A (0.80) | PDE5APDE4BPDE6DPDE6APDE6G | |
| SCHEMBL7005158 | 0.88 | PDE5A (1.00) | PDE5APDE4BNR3C1 | |
| SCHEMBL7955247 | 0.88 | PDE5A (0.76) | PDE5APDE4BPDE6DPDE6APDE6G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6326379-B1 | ERECTILE DYSFUNCTION; CARDIOVASCULAR DISORDERS | BRISTOL-MYERS SQUIBB CO. | 2001-12-04 | — | — | US | disclosed |